Literature DB >> 24715127

A retrospective study of long-term outcomes in 152 patients with primary Sjogren's syndrome: 25-year experience.

Esha Abrol1, Cristina González-Pulido, Juan M Praena-Fernández, David A Isenberg.   

Abstract

The objective of this study was to evaluate the 25-year outcome of patients with primary Sjögren's syndrome (pSS). One hundred and fifty-two patients diagnosed with pSS (American-European classification criteria) were retrospectively and descriptively analysed (1986-2011). Of all 152 patients, 55.9% were alive, 18.4% had died and 25.7% discontinued follow-up (mostly due to old age). Malignancy affected 28.3% and non-Hodgkin's lymphoma (NHL) affected 10.5%. The adjusted risk for development of NHL was an odds ratio (OR) of 10.5 (95% confidence interval [CI]: 3.05-36.42) in patients with vasculitis (p<0.001), and OR 3.4 (95% CI 1.05-11.2) in the presence of glandular complications (parotid swelling, lymphadenopathy) (p < 0.041). Seventy-five patients (49.3%) developed other autoimmune diseases (autoimmune thyroid disease [15.8%], pulmonary fibrosis [7.2%] and vasculitis [10.5%]). Although the course of pSS is relatively benign, over 25 years patients experience more clinical complications than previously described. In addition, vasculitis and glandular manifestations were significant predictors for NHL.

Entities:  

Keywords:  Sjögren’s syndrome; autoimmune diseases; long-term follow-up; neoplasia; non-Hodgkin’s lymphoma

Mesh:

Year:  2014        PMID: 24715127      PMCID: PMC4953287          DOI: 10.7861/clinmedicine.14-2-157

Source DB:  PubMed          Journal:  Clin Med (Lond)        ISSN: 1470-2118            Impact factor:   2.659


  9 in total

1.  Development of new extra-glandular manifestations or associated auto-immune diseases after establishing the diagnosis of primary Sjögren's syndrome : A long-term study of the Antonius Nieuwegein Sjögren (ANS) cohort.

Authors:  E J Ter Borg; J C Kelder
Journal:  Rheumatol Int       Date:  2017-04-19       Impact factor: 2.631

2.  Risk Factors of 131I-Induced Salivary Gland Damage in Thyroid Cancer Patients.

Authors:  Brynn Hollingsworth; Leigha Senter; Xiaoli Zhang; Guy N Brock; Wael Jarjour; Rebecca Nagy; Pamela Brock; Kevin R Coombes; Richard T Kloos; Matthew D Ringel; Jennifer Sipos; Ilene Lattimer; Ricardo Carrau; Sissy M Jhiang
Journal:  J Clin Endocrinol Metab       Date:  2016-08-17       Impact factor: 5.958

3.  Natural History and Predictors of Progression to Sjögren's Syndrome Among Participants of the Sjögren's International Collaborative Clinical Alliance Registry.

Authors:  Caroline H Shiboski; Alan N Baer; Stephen C Shiboski; Mi Lam; Stephen Challacombe; Hector E Lanfranchi; Morten Schiødt; Penelope Shirlaw; Muthiah Srinivasan; Hisanori Umehara; Frederick B Vivino; Esen Akpek; Vatinee Bunya; Cristina F Vollenweider; John S Greenspan; Troy E Daniels; Lindsey A Criswell
Journal:  Arthritis Care Res (Hoboken)       Date:  2018-01-03       Impact factor: 4.794

Review 4.  B-cell survival factors in autoimmune rheumatic disorders.

Authors:  Sandra A Morais; Andreia Vilas-Boas; David A Isenberg
Journal:  Ther Adv Musculoskelet Dis       Date:  2015-08       Impact factor: 5.346

Review 5.  Multiple Roles for B-Lymphocytes in Sjogren's Syndrome.

Authors:  Julian Lawrence Ambrus; Lakshmanan Suresh; Ammon Peck
Journal:  J Clin Med       Date:  2016-10-08       Impact factor: 4.241

6.  Association between EBV serological patterns and lymphocytic profile of SjS patients support a virally triggered autoimmune epithelitis.

Authors:  Filipe Barcelos; Catarina Martins; Ricardo Monteiro; Joana Cardigos; Tiziano Prussiani; Miguel Sítima; Nuno Alves; José Vaz-Patto; Jaime Cunha-Branco; Luís-Miguel Borrego
Journal:  Sci Rep       Date:  2021-02-18       Impact factor: 4.379

7.  A Case of Digital Autoamputation with Concurrent Sjogren's Syndrome, Antiphospholipid Syndrome, and Ovarian Cancer.

Authors:  Esra Keles; Canan Kabaca; Serkan Akis; Zeynep Celik
Journal:  Saudi J Med Med Sci       Date:  2022-08-22

Review 8.  Is primary Sjögren's syndrome a risk factor for malignancies different from lymphomas? What does the literature highlight about it?

Authors:  Ciro Manzo; Melek Kechida
Journal:  Reumatologia       Date:  2017-07-18

9.  The prevalence of ANA antibodies, anticentromere antibodies, and anti-cyclic citrullinated peptide antibodies in patients with primary Sjögren's syndrome compared to patients with dryness symptoms without primary Sjögren's syndrome confirmation.

Authors:  Maria Maślińska; Małgorzata Mańczak; Bożena Wojciechowska; Brygida Kwiatkowska
Journal:  Reumatologia       Date:  2017-07-18
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.